A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Study of TAK-007 in Patients with Non-Hodgkin Lymphoma
Sponsor: Precision BioSciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT7332
U.S. Govt. ID: NCT05020015
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: TAK-007 is being developed as a possible treatment for Lymphoma. TAK-007 is a cell therapy, which means that it consists of live cells that have been modified to help your body to fight Lymphoma. The use of TAK-007 in this study is experimental. Fresh (unfrozen) CAR NK cells, similar to TAK-007, are being tested in another study. In this study, frozen TAK-007 cell therapy will be used for the first time in humans. This means that at present there is less information available regarding the safety and ability to treat cancer with this medication in humans. The main purpose of this study is to test the safety of TAK-007, see how TAK-007 is tolerated by subjects, and understand how well TAK-007 works as a treatment for Lymphoma.
This study is closed
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Non-Hodgkin's Lymphoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator